4 results
DRS/A
MLYS
Mineralys Therapeutics, Inc.
29 Dec 22
Draft registration statement (amended)
12:00am
by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled … and CROs from continuing research and development activities, impede our clinical trial initiation and recruitment and the ability of patients to continue
DRS/A
MLYS
Mineralys Therapeutics, Inc.
7 Dec 22
Draft registration statement (amended)
12:00am
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims … or prevent our employees and CROs from continuing research and development activities, impede our clinical trial initiation and recruitment and the ability
DRS
MLYS
Mineralys Therapeutics, Inc.
4 Nov 22
Draft registration statement
12:00am
of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability … and development activities, impede our clinical trial initiation and recruitment and the ability of patients to continue in clinical trials, including
- Prev
- 1
- Next